SGLT2 inhibitors: the story continues to unfold

被引：3
作者：
Pina, Ileana L. [1 ]
机构：
[1] Cent Michigan Univ, Coll Med, 2627 Fairmount Blvd, Midlands, MI 48640 USA
来源：
EUROPEAN HEART JOURNAL | 2021年 / 42卷 / 48期
关键词：
HEART-FAILURE; SERUM POTASSIUM; OUTCOMES;
D O I：
10.1093/eurheartj/ehab561
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4902 / 4904
页数：3
相关论文
共 50 条
  • [31] Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors
    Vargas-Delgado, Ariana P.
    Arteaga Herrera, Estefania
    Tumbaco Mite, Cesar
    Delgado Cedeno, Patricia
    Van Loon, Maria Cristina
    Badimon, Juan J.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (04)
  • [32] Metabolism of the failing heart and the impact of SGLT2 inhibitors
    Garcia-Ropero, Alvaro
    Santos-Gallego, Carlos G.
    Zafar, M. Urooj
    Badimon, Juan J.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2019, 15 (04) : 275 - 285
  • [33] Class effects of SGLT2 inhibitors on cardiorenal outcomes
    Kluger, Aaron Y.
    Tecson, Kristen M.
    Lee, Andy Y.
    Lerma, Edgar V.
    Rangaswami, Janani
    Lepor, Norman E.
    Cobble, Michael E.
    McCullough, Peter A.
    CARDIOVASCULAR DIABETOLOGY, 2019, 18 (01)
  • [34] Applications of SGLT2 inhibitors beyond glycaemic control
    O'Hara, Daniel V.
    Lam, Carolyn S. P.
    Mcmurray, John J. V.
    Yi, Tae Won
    Hocking, Samantha
    Dawson, Jessica
    Raichand, Smriti
    Januszewski, Andrzej S.
    Jardine, Meg J.
    NATURE REVIEWS NEPHROLOGY, 2024, 20 (08) : 513 - 529
  • [35] SGLT2 inhibitors: practical considerations and recommendations for cardiologists
    Opingari, Erika
    Partridge, Arun C. R.
    Verma, Subodh
    Bajaj, Harpreet S.
    CURRENT OPINION IN CARDIOLOGY, 2018, 33 (06) : 676 - 682
  • [36] SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection
    Bell, Robert M.
    Yellon, Derek M.
    LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (06) : 435 - 437
  • [37] SGLT2 inhibitors to prevent diabetic kidney disease
    Fioretto, Paola
    Vettor, Roberto
    Pontremoli, Roberto
    LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (01) : 4 - 5
  • [38] Extrarenal Benefits of SGLT2 Inhibitors in the Treatment of Cardiomyopathies
    Yerra, Veera Ganesh
    Connelly, Kim A.
    PHYSIOLOGY, 2024, 39 (06) : 412 - 434
  • [39] SGLT2 inhibitors and heart failure - clinical implications
    Raz, Itamar
    Cahn, Avivit
    NATURE REVIEWS CARDIOLOGY, 2016, 13 (04) : 185 - 186
  • [40] SGLT2 inhibitors for primary prevention of cardiovascular events
    Raz, Itamar
    Cernea, Simona
    Cahn, Avivit
    JOURNAL OF DIABETES, 2020, 12 (01) : 5 - 7
12345